Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News FDA approves Eisai and Merck’s Lenvima for first-line treatment of liver cancer In a significant development for cancer treatment, Eisai and Merck have announced that the U.S. Food and Drug… bypharmanewsdailyAugust 18, 2018
